Vitrolife Group (VITR) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales reached SEK 941 million, up 4% year-over-year in local currencies, with strong Technologies growth and improved margins.

• Gross margin increased to 59.9% (up from 55.8%), and EBITDA margin rose to 34.7% (up from 32.4%), driven by favorable product mix and operational efficiencies.

• Net income rose to SEK 143 million (from SEK 106 million), and earnings per share increased to SEK 1.06 (from SEK 0.78).

• Acquisition of eFertility completed, supporting digitalisation, automation, and strategic platform expansion in IVF clinic management.

• No significant events occurred after the reporting period.

Financial highlights

• Q2 2024 EBITDA was SEK 327 million (up from SEK 293 million), with an EBITDA margin of 34.7%.

• Operating cash flow was SEK 236 million (up from SEK 211 million year-over-year).

• Net income for Q2 2024 was SEK 143 million, net income margin 15.3%.

• Net debt/EBITDA improved to 1.0 (from 1.3 year-over-year).

• Equity/assets ratio: 77.7% (81.7% in Q2 2023).

Outlook and guidance

• Strategic focus on increasing market share in the US and China, consumables growth, and accelerating adoption of Time-Lapse and genetics portfolio.

• Continued investment in commercial capabilities and operational excellence to drive growth.

• IVF cycles expected to grow globally by 5-7% annually, driven by demographic trends and supportive policies.

• Gross margin at ~60% seen as challenging to sustain, with some potential dilution from genomic kits.

• Genetic services expected to see steady, profitable growth, with a positive outlook for H2.